# NHLBI Training Program in Pharmacoepidemiology

> **NIH NIH T32** · JOHNS HOPKINS UNIVERSITY · 2024 · $317,361

## Abstract

PROJECT SUMMARY / ABSTRACT
Pharmacoepidemiology is a bridge science that uses tools from pharmacology, epidemiology and clinical
medicine to understand the use, safety and effectiveness of drugs in large populations. The need for experts in
this field is as great as ever before. During the past decade, dozens of new therapies have been brought to
market, including products made from living cells, or biologics, to address common and costly heart, lung and
blood conditions ranging from cystic fibrosis to thromboembolism to Hemophilia A. With the rise in access to
promising yet expensive drugs comes the need to study their benefits and risks in diverse populations as well
as to understand best use of these medicines to improve human health. In addition, many of
pharmacoepidemiology’s tools and methods are also highly relevant to the study of use, safety and effectiveness
of other medical products including diagnostics, devices, and drug-device combinations. We propose to renew
our heretofore highly successful training program in pharmacoepidemiology for pre- and post-doctoral trainees
at the Johns Hopkins Bloomberg School of Public Health and Johns Hopkins School of Medicine. These
institutions remain exceptionally well suited to this task. The Bloomberg School of Public Health is the oldest and
largest School of Public Health in the world, while the Johns Hopkins School of Medicine is an internationally
renowned leader in scientific research and clinical medicine. Continuing our program will leverage a wealth of
human capital and material resources at Johns Hopkins to provide comprehensive, longitudinal, and integrated
training and professional development opportunities to future leaders in the field. We will use this award to train
scientists who will identify and address fundamental questions about the use, safety and effectiveness of
medicines and other medical products for the treatment of heart, lung and blood diseases. Given the strengths
of our faculty and trainee pool, we will also support the development of innovative methods to do so. Thus, our
trainees will develop skills to generate evidence that can be used to address the needs of patients, clinicians,
payers, regulators and other stakeholders, and in so doing, improve the optimal use of medicines to treat heart,
lung and blood diseases in the United States.

## Key facts

- **NIH application ID:** 10766986
- **Project number:** 2T32HL139426-06A1
- **Recipient organization:** JOHNS HOPKINS UNIVERSITY
- **Principal Investigator:** G. Caleb Alexander
- **Activity code:** T32 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $317,361
- **Award type:** 2
- **Project period:** 2018-01-01 → 2029-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10766986

## Citation

> US National Institutes of Health, RePORTER application 10766986, NHLBI Training Program in Pharmacoepidemiology (2T32HL139426-06A1). Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/grant/nih/10766986. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*